Menu top

• Home
• About PH&T
• Our Products
• Therapeutic Areas
• Contacts

About PH&T

• Business Model
• Facts & Figures

Generics

• Alfuzosin
• Amiodarone
• Budesonide
• Calcitriol
• Desmopressin
• Donepezil
• Dorzolamide & Timolol
• Epoprostenol
• Exemestane
• Flutamide
• Glyceryl trinitrate
• Latanoprost
• Latanoprost & Timolol
• Megestrol acetate
• Mometasone furoate
• Nifedipine
• Somatostatin
• Travoprost
• Zoledronic acid

Medical Devices

• Rinar
• Turbospin DPI

Therapeutic Areas

• Cardiovascular
• CNS / Neurology
• Endocrine & Metabolic diseases
• Gastrointestinal
• Genitourinary System
• Oncology
• Ophtalmology
• Respiratory System

Contacts

• Contact Details
• How To Reach Us

Footer Menu

• Privacy
• Disclaimer
• Copyright
• Site Map
• Useful links
• WebProject by EBS 

• News
  • News
    • Zydus Cadila succesfully launched Turbospin licensed by PH&T
    • PH&T at CPhI 2010
    • PH&T and STADA Asia announce their agreement for Latanoprost and Alfuzosin
    • Exemestane significantly reduces risk of breast cancer
    • Exemestane PH&T proved bioequivalent to Aromasin (Pfizer)
    • Alfuzosin PH&T 10 mg. prolonged release tablets has been registered in Philippines by STADA
    • Epoprostenol PH&T received Marketing Authorization
    • Somatostatin PH&T Vietnam
    • Latanoprost showed full therapeutical equivalence
    • READ MORE NEWS
• Redirect
• News Archive